• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Adaptimmune Therapeutics plc

    2/12/25 10:25:35 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Adaptimmune Therapeutics PLC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    00653A107

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00653A107


    1Names of Reporting Persons

    BAILLIE GIFFORD & CO
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    70,914,570.00
    6Shared Voting Power

    7Sole Dispositive Power

    70,914,570.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    70,914,570.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Adaptimmune Therapeutics PLC
    (b)Address of issuer's principal executive offices:

    60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM, OX14 4RX.
    Item 2. 
    (a)Name of person filing:

    Baillie Gifford & Co
    (b)Address or principal business office or, if none, residence:

    Calton Square 1 Greenside Row Edinburgh EH1 3AN Scotland UK
    (c)Citizenship:

    Scotland
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    00653A107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Investment Adviser
    Item 4.Ownership
    (a)Amount beneficially owned:

    70,914,570 (These are held as 11,819,095 American Depositary Shares [ADS] with six ordinary shares representing one ADS.)
    (b)Percent of class:

    4.62  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    70,914,570 (These are held as 11,819,095 American Depositary Shares [ADS] with six ordinary shares representing one ADS.)

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    70,914,570 (These are held as 11,819,095 American Depositary Shares [ADS] with six ordinary shares representing one ADS.)

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Adviser is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BAILLIE GIFFORD & CO
     
    Signature:Grant Meikle
    Name/Title:Threshold & Transaction Reporting Manager
    Date:02/12/2025
    Get the next $ADAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAP

    DatePrice TargetRatingAnalyst
    7/30/2024$4.00Buy
    H.C. Wainwright
    5/30/2024$3.15Sector Outperform
    Scotiabank
    3/24/2023$3.60Buy
    Bryan Garnier
    1/3/2023$5.00Neutral → Buy
    Guggenheim
    11/9/2022$9.00Neutral → Buy
    Mizuho
    9/22/2021$6.00 → $7.00Equal-Weight
    Wells Fargo
    9/13/2021$6.00 → $7.00Market Perform
    SVB Leerink
    9/7/2021$5.00 → $6.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    SEC Filings

    See more
    • Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      5/1/25 4:15:32 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adaptimmune Therapeutics plc

      DEF 14A - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/25/25 8:02:51 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Adaptimmune Therapeutics plc

      S-3 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/18/25 4:32:27 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Adaptimmune Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00

      7/30/24 6:31:41 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptimmune Therapeutics with a new price target

      Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15

      5/30/24 7:25:43 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bryan Garnier initiated coverage on Adaptimmune Therapeutics with a new price target

      Bryan Garnier initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $3.60

      3/24/23 9:09:04 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ADAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADAP
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      11/13/24 9:04:55 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13D/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      4/2/24 8:38:07 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      3/26/24 11:59:28 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:35:34 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:34:48 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Patient Supply Officer Lunger John

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:33:25 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Financials

    Live finance-specific insights

    See more
    • Adaptimmune Reports Q3 2024 Financial and Business Updates

      Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million

      11/13/24 4:05:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Reports Q2 2024 Financial and Business Updates

      Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive ordersAt the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 millionPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) tod

      8/12/24 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

      Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*0

      8/1/24 8:20:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care